InterCure Wins Cannolam Arbitration Proceeding
NEW YORK and HERZLIYA, Israel , Oct. 31, 2023 (GLOBE NEWSWIRE) — InterCure Ltd. (NASDAQ:INCR) (TASE: INCR) (dba Canndoc) (“InterCure” or the “Company“), the leading medical cannabis company in Israel and outside of North America, reports today that, further to the Company’s press release issued on August 31, 2023, in which the Company reported that the Tel Aviv-Jaffa District Court dismissed the lawsuit that filed against the Company by minority shareholders of its subsidiary, Cannolam Ltd. (“Cannolam”), and the parties agreed on a binding arbitration process (the “Arbitration”), in which the amount owed to the Company and the parties will be determined and paid as part of a full separation process, the Company hereby reports that the Arbitration has been concluded, and the arbitrator has decided in favor of the Company on most of the claims presented to him by the Company, while rejecting almost all of the claims presented by the minority shareholders.
Related news for (INCR)
- intercure announces first half of 2024 results: revenue of nis 126 million and adjusted ebitda of nis 21 million
- intercure announces expansion of its strategic partnership with cookies to germany
- InterCure Signs Definitive Agreement to Acquire Leon Cannabis Pharmacy Chain
- InterCure Announces Record Fourth Quarter and Fiscal Year End 2022 Results